RDSNFRedsense Medical AB

About Redsense Medical AB (RDSNF)

Redsense Medical AB (RDSNF) is a Medical Devices company headquartered in Halmstad, Sweden whose shares trade over-the-counter on the Pink tier.

Redsense Medical AB is a born-global medical device innovator established in Sweden. Redsense's mission is to improve the safety and quality of life for dialysis patients worldwide. The group has its main market in the United States as well as sales in Europe and Canada. Redsense promotes patient safety through highly cost-efficient fiber-optic monitoring of the blood access site during hemodialysis. The Redsense System immediately detects Venous Needle Dislodgement (VND) - a potentially life-threatening complication that causes 21 avoidable deaths per week worldwide. In essence, the Redsense alarm provides patients, nurses, and caregivers an extra pair of eyes; always alert, focused on one thing only, never looking away. Redsense products are used in both clinics and at home, daily and nocturnally. Today, the majority of treatments are performed in clinical settings, but home treatment is gaining popularity thanks to lower cost, increased convenience for the patient, improvements in technology and political initiative. The number of patients undergoing hemodialysis several times per week due to chronic kidney disease is approaching 4 million, worldwide. The projected growth rate is six percent annually, driven by ageing population and other factors. Every hemodialysis treatment carries the risk of VND. In the last years more than 1 million treatments have been conducted with the Redsense System worldwide.

Products and services

Redsense Medical has developed the Redsense System, an innovation used for monitoring hemodialysis treatment and alarming in the event of blood leakage. The system consists of a patented fiber optic sensor which is embedded in a disposable patch designed for either a venous needle or central venous catheter, which is then connected to an alarm unit and is triggered when the sensor comes into contact with blood so one can address the issue immediately and stop the blood flow. From the very start, development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The system is the only blood leakage system on the market that is both CE marked and FDA cleared for sales in the USA. In more than 15 years of clinical use, patients and nurses have felt safer when using the Redsense alarm system to detect VND. Redsense is proud to count the 5 largest dialysis providers in the USA among users of the Redsense blood leakage system. The US department of Veteran Affairs even mandates the use of Redsense System for hemodialysis treatments. Most recently, Redsense has engaged in R&D into the Redsense Clamp, a device that works directly with the Redsense alarm that, when triggered, automatically closes the venous bloodline, preventing additional blood loss. The Redsense Clamp is expected to be launched in 2024.

RDSNF key facts

Ticker symbol

RDSNF

Market tier

Pink

Sector

Healthcare

Industry

Medical Devices

Headquarters

Halmstad, Sweden

Country of incorporation

SE

Year of incorporation

2003

Employees

5

Estimated market cap

$8.39M (as of May 13, 2025)

Shares outstanding

16,444,891

Reporting standard

International Reporting: Spotlight Stock Market

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2024)

Redsense Medical AB leadership

• Sebastien Kathleen Philippe Bollue — COO
• Jennie Kardell — CFO, CEO
• Ann-Marie Eriksson — CTO

Explore more: Medical Devices stocks · Healthcare sector · Pink stocks · OTC stocks starting with R